ELI LILLY TO MAKE COVID-19 ANTIBODY DRUG COMMERCIALLY AVAILABLE FROM AUGUST
Eli Lilly plans to make its COVID-19 antibody drug commercially available to U.S. states as well as hospitals and other healthcare providers in August. The drug, bebtelovimab, had received authorization in the United States in February for the treatment of mild-to-moderate COVID-19 among adults and children. Lilly would make bebtelovimab commercially available through a sole distributor beginning the week of Aug. 15. This will be done under the existing emergency use authorization, adding that it currently does not plan to pursue full approval for bebtelovimab.
Full Access: Reuters
INFANT EXPOSURE TO ACID SUPPRESSANT MEDICATIONS INCREASES RISK OF RECURRENT WHEEZE AND ASTHMA IN CHILDHOOD
Of the 921 children in this cohort study, 202 (22%) were exposed to Acid Suppressant Medications (ASMs) during infancy. Compared to unexposed children, those exposed to ASM were more likely to develop recurrent wheeze by age 3 years (95%CI 1.20-2.08, P=0.001) and asthma by age 6 years (95%CI 1.22-2.27, P=0.001). While exposure to ASMs during infancy does not increase the risk of allergen sensitization in early childhood, but it increases the risk of recurrent wheeze and asthma during early childhood.
Full Access: Journal of Allergy and Clinical Immunology
BIOHAVEN SURVEY UNCOVERS PATIENT-DOCTOR COMMUNICATION GAPS FOR MIGRAINES AND MENTAL HEALTH
According to a new survey on migraines and mental health by the American Migraine Foundation and Biohaven Pharmaceutical, two-thirds of patients said it was important to discuss mental health with the Health Care Professional (HCP) treating their migraine, more than three-quarters (77%) said they worried about stigma and were hesitant to broach the topics. The online survey conducted between April and May 2022, polled 1,100 people who had both migraine and a mental health condition as well as 302 Health Care Professionals (HCPs) who treat neurological diseases including neurologists, headache specialists and general practitioners.
Full Access: Fiercepharma
CDC RESPONSE TO DOXY-PEP DATA PRESENTED AT 2022 INTERNATIONAL AIDS CONFERENCE
JULY 27, 2022 – CDC RESPONSE TO PRESENTATION OF DOXY-PEP CLINICAL TRIAL DATA AT 2022 INTERNATIONAL AIDS CONFERENCE
CDC commented on the the initial data from the NIH- funded study on the use of doxycycline post-exposure prophylaxis (doxy-PEP) to prevent STIs infections. The first look at the data presented at the 2022 International AIDS Conference showed doxy-PEP demonstrated significant effectiveness and tolerability against these common STIs in gay and bisexual men and transgender women with HIV or taking HIV pre-exposure prophylaxis (PrEP) over the course of this study.
Full Access: CDC
DIETARY RISK FACTORS FOR INCIDENT AND RECURRENT SYMPTOMATIC KIDNEY STONES
This prospectively recruited 411 local incident symptomatic kidney stone formers (medical record validated) and 384 controls who were seen at Mayo Clinic in Minnesota or Florida between January 1, 2009, and August 31, 2018. Dietary factors were based on a Viocare, Inc, food frequency questionnaire administered during a baseline in-person study visit. In fully adjusted analyses, lower dietary calcium, potassium, caffeine, phytate, and fluid intake were all associated with a higher odds of an incident symptomatic kidney stone. Among incident stone formers, 73 experienced symptomatic recurrence during a median 4.1 years of follow-up.
Full Access: Mayo Clinic